Thermo Fisher Scientific Inc.(NYSE: TMO) has signed a long-term license agreement with Japansese firm Fujirebio Inc. to make its test for the early detection of sepsis available on the Japanese firms’ laboratory instruments. Fujirebio’s Lumipulse product line of lab instruments is used in a significant number of hospitals and clinical reference labs in Japan and will be extended with future placements of Lumipulse platforms in other markets worldwide. The terms of the deal were not disclosed. “This agreement with Fujirebio ensures that PCT testing will be available to a much broader patient base, helping to improve patient’s outcome,” Marc Tremblay, president of Thermo Fisher Scientific’s Clinical Diagnostics business, said in a statement. “Through the earlier detection of sepsis, healthcare providers can offer much better treatment to their patients and also achieve dramatic cost savings.”
